Component-resolved in vitro diagnosis of hazelnut allergy in Europe - 13/08/11
, Barbara K. Ballmer-Weber, MD, PhD b, Joaquin Sastre, MD, PhD c, Jonas Lidholm, PhD d, Kerstin Andersson, PhD d, Hubert Oberhofer, MD b, Magdalena Lluch-Bernal, MD c, Jonas Östling, PhD d, Lars Mattsson, PhD d, Frauke Schocker, PhD e, Stefan Vieths, PhD f, Lars K. Poulsen, PhD a
Reprint requests: Kirsten Skamstrup Hansen, MD, PhD, Allergy Clinic, National University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.Abstract |
Background |
Food allergy to hazelnut occurs both with and without concomitant pollen allergy.
Objective |
We sought to evaluate a panel of hazelnut allergens for diagnosis of hazelnut allergy in Spain, Switzerland, and Denmark.
Methods |
Fifty-two patients with a positive double-blind, placebo-controlled food challenge result with hazelnuts; 5 patients with a history of anaphylaxis; 62 patients with pollen allergy but hazelnut tolerance; and 63 nonatopic control subjects were included. Serum IgE levels to hazelnut extract, recombinant hazelnut allergens (rCor a 1.04, rCor a 2, rCor a 8, rCor a 11), and native allergens (nCor a 9, nCor a Bd8K, nCor a Bd11K) were analyzed by means of ImmunoCAP.
Results |
Among patients with hazelnut allergy, 91% (Switzerland/Spain, 100%; Denmark, 75%) had IgE to hazelnut extract, 75% to rCor a 1.04, 42% to rCor a 2, 28% to rCor a 8, and 2% to rCor a 11. The highest rate of sensitization to Cor a 1.04 was found in the northern regions (Switzerland/Denmark, 100%; Spain, 18%), whereas IgE to the lipid transfer protein rCor a 8 prevailed in Spain (Spain, 71%; Switzerland, 15%; Denmark, 5%). IgE to profilin rCor a 2 was equally distributed (40% to 45%). Among control subjects with pollen allergy, 61% had IgE to hazelnut extract, 69% to rCor a 1.04, 34% to rCor a 2, 10% to rCor a 8, and 6% to rCor a 11.
Conclusion |
Component-resolved in vitro analyses revealed substantial differences in IgE profiles of hazelnut allergic and hazelnut tolerant patients across Europe.
Il testo completo di questo articolo è disponibile in PDF.Key words : Birch pollen, Cor a 1, double-blind, placebo-controlled food challenge, food allergy, hazelnut, IgE, lipid transfer protein, recombinant allergens
Abbreviations used : CCD, DBPCFC, LTP, OAS, SPT
Mappa
| Supported by Phadia AB, Uppsala, Sweden. |
|
| Disclosure of potential conflict of interest: K. S. Hansen has received research support from ALK-Abelló, Novo-Nordic, Schering-Plough, and Nutricia and has provided expert testimony on allergy prophylaxis, infant feeding, and allergy to fungi for the National Board of Health, Denmark. J. Sastre has served as a consultant for ALK-Abelló, GlaxoSmithKline, Novartis, and Phadia; has received research funding from the European Union, NIDHS, and the Spanish Ministry of Health; and serves as an invest section chair for the European Academy of Allergology and Clinical Immunology (EAACI). F. Schocker has received an honorarium for the transfer recombinant protein from Phadia, Uppsala, Sweden, and has received research support from the German Research Society. S. Vieths is an associate of the Institute for Product Quality, Berlin, Germany; has received an honoraria from Phadia, Uppsala, Sweden, the Food Allergy Resource and Research Program, and Mars Chocolate UK Ltd and Mars Nederland BV; has received research support from European Union, the German Research Society, the Research Fund of the German Food Industry, Monsanto Company, Pioneer Hi-Breed International, Inc, and the European Directorate for the Quality of Medicines and Health Care; and has served as the Chairman of the Food Allergy Interest Group for the EAACI, Chairman of the Allergen Standardization Subcommittee and Secretary of the Allergen Nomenclature Subcommittee for the International Union of Immunological Societies, a registered expert for the European Agency for the for the Evaluation of Medicinal Products and the European Pharmacopoeia Commission, a scientific advisor for ILSI Health and Environmental Science Institution, the Protein Allergenicity Technical Committee, Chairman of the Technical Committee for the European Committee for Standardization, and a member of the Food Allergy Working Group of the German Society for Allergy and Clinical Immunology. L. K. Poulsen has received research support from Phadia. The rest of the authors have declared that they have no conflict of interest. |
Vol 123 - N° 5
P. 1134 - Maggio 2009 Ritorno al numero
Articolo precedente
- Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis
- Jens-Michael Jensen, Stephan Pfeiffer, Magdalena Witt, Matthias Bräutigam, Claudia Neumann, Michael Weichenthal, Thomas Schwarz, Regina Fölster-Holst, Ehrhardt Proksch
- Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects
- Aikaterini Detoraki, Rosaria I. Staiano, Francescopaolo Granata, Giorgio Giannattasio, Nella Prevete, Amato de Paulis, Domenico Ribatti, Arturo Genovese, Massimo Triggiani, Gianni Marone
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?